Table 2.
Summary of the drugs for combating COVID-19 that are under clinical trials.
| Therapeutic Agent | Current Status | Rout of Administration | Purpose of Study | Clinical Trial Identification |
|---|---|---|---|---|
| Remdesivir | Phase III | Intravenous | Antiviral drug to manage COVID-19 |
NCT04678739 NCT04647695 NCT04582266 NCT04738045 |
| Chloroquine | Phase I/II/IV | Oral | Antimalarial drug to treat mild Asymptomatic and Symptomatic cases of COVID-19 |
NCT04443270 NCT04328493 NCT04627467 |
| Lopinavir/ ritonavir |
Phase IV/II | Intravenous | Antiviral drug to treat COVID-19 in terminally sick patients with cancer and immune suppression |
NCT04738045 NCT04455958 |
| Azithromycin | Phase III/IV | Oral | Antibiotic drug to treat COVID-19 patients |
NCT04365231 NCT04359316 |
| Hydroxy-chloroquine | Phase II/I | Oral | Antimalarial drug to treat ambulatory patients with mild and severe COVID-19 |
NCT04340544 NCT04351620 |
| Arbidol | Phase IV | Oral | Antiviral drug to treat COVID-19 patients | NCT04350684 |
| Isotretinoin | Phase III | Oral | Retinoid drug to evaluate the safety and efficacy in treatment of COVID-19 |
NCT04663906 NCT04353180 |
| Lenalidomide | Phase IV | Oral | Antiangiogenic drug to treat mild COVID-19 patients | NCT04361643 |
| Chlorpromazine | Phase III | Oral | Antipsychotics drug to manage COVID-19 subjects | NCT04366739 |
| Canakinumab | Phase III | Intravenous | Anti-human-IL-1β monoclonal antibody to study the efficacy in treating COVID-19 patients | NCT04362813 |
| Ruxolitinib | Phase III | Oral | Antiviral drug to assay the efficacy in COVID-19 patients with cytokine storm | NCT04362137 |
| Dexamethasone | Phase IV | Intravenous | Steroid drug to treat COVID-19 patients | NCT04325061 |
| Favipiravir | Phase III | Oral | Antiviral drug to treat COVID-19 patients | NCT04336904 |
| Sildenafil citrate | Phase III | Oral | Phosphodiesterase inhibitor drug to treat COVID-19 patients | NCT04304313 |